1 SUPPLEMENTAL MATERIAL



2

3 Suppl. Figure 1. Sub-population composition of T and NK cells from COVID-19 patients.

(A) UMAP visualization for the subclustering of T and NK cells selected PBMC of 7 COVID-19 patients
(18 samples obtained at days 0, 5 and 15 post admission) and 6 healthy controls. Twelve major subpopulations were identified. (B) UMAP visualization of sixteen major T cell marker genes used to validate
sub-populations annotation. (C) Heatmap representation of the normalized expression in each individual Tcell subpopulation for the top 74 genes identified as sub-population specific markers using the Seurat
'FindAllMarkers' function.



10

11 Suppl. Figure 2. Sub-population composition of B cells from COVID-19 patients.

(A) UMAP visualization of B cell sub-populations selected from 7 COVID-19 patients (18 samples obtained at days 0, 5 and 15 of admission) and 6 healthy controls. Four major sub-populations are identified.
(B) UMAP visualization of twelve major B-cell marker genes used to validate sub-population annotation.
(C) Heatmap representation of the normalized expression in each individual B-cell subpopulation for the top 37 genes identified as sub-population specific markers using the Seurat 'FindAllMarkers' function.



18

19 Suppl. Figure 3. Sub-population composition of Myeloid cells from COVID-19 patients.

(A) UMAP visualization of Myeloid cells subclustering selected from PBMC of 7 COVID-19 patients (18
samples obtained at days 0, 5 and 15 of admission) and 6 healthy controls. Seven major sub-populations
were identified. (B) UMAP visualization of twelve marker genes used to validate sub-population
annotation. (C) Heatmap representation of the normalized expression in each Myeloid cell subpopulation
for the top 50 genes identified as sub-population specific markers using the Seurat 'FindAllMarkers'
function.





27 Suppl. Figure 4. PBMC sub-population cell proportions

Box and whisker plots for the proportion of cells for each subpopulation of T cells (A), B cells (B) and Myeloid cells (C) for samples in each clinical group; expressed as % of total PBMC. Lineage proportions at days 5 and 15 of COVID-19 patients classified based on the disease OS and grouped as Moderate(cyan) or Critical(purple). Corresponding values from healthy controls (red) and from all COVID-19 patients at admission (green) are provided as reference groups. Q-values for pairwise t-test between Critical and Moderate comparisons are provided when significant.







41 Suppl. Figure 5. Evolution of the transcriptional expression for enriched GO-terms.

42 Differentially expressed genes contributing to GO term enrichment (indicated on the left axis and displayed 43 in Figure 4A) have been used to generate a Module Score representing the overall transcriptional expression 44 level for the specific category. Corresponding cell populations are listed at the bottom of the graph. Module 45 scores have been computed for the Day 0 and Day 5 time-points for each cell population and based on 46 "Deceased" and "Alive" COVID-19 patient outcomes separately. Control samples from healthy subjects 47 are included as reference. Sample groups are coloured according to the key on top of the graph. The 48 significance of the gene expression differences between "Deceased vs Alive" COVID-19 patients was 49 tested by comparing the corresponding Module Score distribution in every group of cells using a wilcoxon rank-test approach (q-value ≤ 0.05). To provide a sample-size free evaluation of the difference in 50 51 expression, Cohen's d effect size estimation is shown above each significant variation observed.



54 Suppl. Figure 6. COVID-19 WHO clinical ordinal scale correlates with chromatin stability of
55 CD14+ monocytes.

56 (A) The fraction of reads in peaks (FRIP) for CD14+ monocytes, a surrogate for chromatin stability, was
57 plotted against the date of PBMC collection. The WHO ordinal scale for COVID-19 is shown for all patients

at each timepoint. (B) Correlation of the FRIP with WHO clinical scale score for COVID-19. Samples are

59 labeled according to the donor ID, day of collection and patient outcome.

716 More close peaks in deceased at Admission

Nomo	MOTIE	# of DAC	% of DAC	# random	% of random	# peaks at	% peaks at	o voluo	FDR	
Name	MOTIF	with Motif	with Motif	Motif	Motif	with Motif	with Motif	p-value	q-value	
			Group 1 - NF	Y						
NFY	agccaatese	282	49.3%	12676	27.4%	1356	34.9%	1.0E-28	< 5.0E-05	
Group 2 - Sp1-like/KLF										
Sp1	SCCCCCCCCC	297	51.9%	14991	32.4%	1592	40.9%	1.0E-21	< 5.0E-05	
KLF3	SACCESCOCCESES	308	53.9%	16188	34.9%	1642	42.2%	1.0E-19	< 5.0E-05	
KLF1	87GCG7GGGGCX	404	70.6%	24860	53.7%	2318	59.6%	1.0E-16	< 5.0E-05	
KIf9	GCCACXCCCAC	238	41.6%	13083	28.2%	1256	32.3%	1.0E-11	< 5.0E-05	
Sp5	<u><u><u>eg</u>lgggggggggg</u>gggggggggggggggggggggg</u>	409	71.5%	27005	58.3%	2488	64.0%	1.0E-10	< 5.0E-05	
Klf4	GCCACACCCA	189	33.0%	10073	21.7%	968	24.9%	1.0E-09	< 5.0E-05	
KLF5	TUUUEUEUEU	419	73.3%	29349	63.4%	2612	67.2%	1.0E-06	< 5.0E-05	
KLF6	ACCOT COCCOS	389	68.0%	26803	57.9%	2389	61.4%	1.0E-06	< 5.0E-05	
Egr2	CCCCTCTCTCCC	136	23.8%	7583	16.4%	671	17.3%	1.0E-05	< 5.0E-05	
KLF10	COGGCCCC	193	33.7%	12843	27.7%	1100	28.3%	1.0E-03	5.6E-03	
Maz	66280966	412	72.0%	30442	65.7%	2200	66.0%	1.0E-03	4.5E-03	
EDEA	GCCCGGAAAT	979	47 7%	17126	37.04	1620	41.0%	1.05-07	< F.0E.05	
E2E7	SATTTCCCCCA	101	17 7%	5981	12 7%	556	14.3%	1.05-07	2 8E-03	
E2E6	SCCGGGAAAS	274	47.9%	18963	40.9%	1642	42.2%	1.0E-03	3.0E-03	
E2F1	SIGCOCCAA	173	30.2%	11181	24.1%	996	25.6%	1.0E-03	3.3E-03	
E2F3	TTGGCCGGGAAA	298	52.1%	20918	45.2%	1818	46.8%	1.0E-03	3.3E-03	
	CRASUMUSEDVE		Group 4 - MY	'B						
MYB	GGCSGTTA	369	64.5%	23351	50.4%	2064	53.1%	1.0E-11	< 5.0E-05	
AMYB	IGSCACTTOS	302	52.8%	19292	41.6%	1815	46.7%	1.0E-07	< 5.0E-05	
	CAPYONI OC		Group 5 - CF	E						
CRE	SESTGACGTCAS	114	19.9%	5163	11.1%	599	15.4%	1.0E-09	< 5.0E-05	
			Group 6 - HO	x						
Hoxa9		362	63.3%	24219	52.3%	2058	52.9%	1.0E-07	< 5.0E-05	
Hoxd10	SECONTRAAS	190	33.2%	11890	25.7%	1069	27.5%	1.0E-04	3.0E-04	
			Group 7 - PE	x						
Pknox1	FEIGICAETCAE	75	13.1%	3567	7.7%	308	7.9%	1.0E-05	1.0E-04	
Pbx3	SCIGICACICAC	66	11.5%	3201	6.9%	263	6.8%	1.0E-04	4.0E-04	
PBX1	<u>Sectetca</u>	30	5.2%	1072	2.3%	84	2.2%	1.0E-04	4.0E-04	
MafA	LIGCTIGACINA	165	28.9%	10200	22.0%	896	23.0%	1.0E-04	7.0E-04	
	T00140000		Group 8 - ZNF	189						
ZNF189	LGGAASEGEE	203	35.5%	12778	27.6%	1056	27.2%	1.0E-04	3.0E-04	
	SECTANTIAG	G	iroup 9 - LIM hon	leobox						
En1		271	47.4%	18020	38.9%	1600	41.1%	1.0E-04	3.0E-04	
ISI1	CTAATTOS	280	49.0%	18856	40.7%	1596	41.0%	1.0E-04	4.0E-04	
LRX3	II MAGY\$	230	40.2%	10145 Sov17	32.7%	1241	31.9%	1.0E-04	8.0E-04	
Oct/-Sov17	SCATTCTATCCAAAI	93	5.8%	1020	2.6%	65	1 7%	1.05-04	3.0E-04	
000000000	9XA11ATA1AAAA68	55	Group 11 - Fr)X	a.070		1.7.79	1.02-04	0.06-04	
Foxh1	SETCTCCATTES	115	20.1%	6695	14.5%	556	14.3%	1.0E-03	1.2E-03	
Foxo1	CTGTTTAC	288	50.4%	19992	43.2%	1734	44.6%	1.0E-03	2.3E-03	
	STV21254		Group 12 - GA	TA						
GATA	CONCERNENCE OF CONCERNENCE OF CONCE	32	5.6%	1394	3.0%	120	3.1%	1.0E-03	4.6E-03	
	COULCAL ALL COVER ANALO		Group 13 - TI	зх						
Tbx20	SETCETCACAGE	56	9.8%	2936	6.3%	258	6.6%	1.0E-03	5.8E-03	
			Group 14 - N	KX.						
Amt:Ahr		194	33.9%	12608	27.2%	1154	29.7%	1.0E-03	1.8E-03	
Nkx2.2	TERCACGCA	336	58.7%	24193	52.2%	1946	50.0%	1.0E-03	5.9E-03	
Nkx2.1	Setgastcasts	404	70.6%	29952	64.7%	2395	61.6%	1.0E-02	7.9E-03	
Group 15 - ZNF669										
ZNF669	XAXIGGTCATCSCCC	45	7.9%	2290	4.9%	170	4.4%	1.0E-02	9.4E-03	

243 More open peaks in deceased at Admission

Name	MOTIF	# of DAC with Motif	% of DAC with Motif	# random peaks with Motif	% of random peaks with Motif	# peaks at FDR > 50% with Motif	% peaks at FDR > 50% with Motif	p-value	FDR q-value		
Group 16 - IRF											
PU.1:IRF8	GGAAGTGAAASI	35	16.6%	2597	5.2%	346	9.8%	1.0E-08	< 5.0E-05		
IRF8	GEAAEIGAAAEI	43	20.4%	4285	8.7%	541	15.3%	1.0E-06	< 5.0E-05		
IRF2	SAAASEGAAASE	17	8.1%	1279	2.6%	193	5.5%	1.0E-04	1.5E-03		
IRF4	2010 CONTRACTOR	37	17.5%	4711	9.5%	451	12.8%	1.0E-03	3.8E-03		
Group 17 - CTCF											
CTCF	ATTERCESTCOCE	30	14.2%	3261	6.6%	324	9.2%	1.0E-04	1.8E-03		
BORIS	STATEFFCCCCCCCTSEIGGE	53	25.1%	7884	15.9%	603	17.1%	1.0E-03	5.9E-03		
Group 18 - MADS											
CArG	CCATATATGGSe	29	13.7%	3423	6.9%	236	6.7%	1.0E-03	5.2E-03		

61 Suppl Figure 7. Motif homology groping for the 46 transcription factors enriched in DAC regions

62 of deceased patients at Admission.

The 46 transcription factors significantly enriched in DAC regions of deceased patients at FDR <1% are shown with their respective motif binding sequences in each row. Transcription factors were grouped based on the sequence homology of their binding motif. The number and percentage of peaks with motifs corresponding to the heatmap in figure 4D is shown for DAC, random peaks, and peaks at FDR > 50% in the center columns. Uncorrected *p*-value and the FDR q-value for the contrast between DAC and random regions is given in the last two columns.



71 Suppl Figure 8. Chromatin accessibility at promoters of transcription factors with binding motifs

72 enriched in repressed DAC regions of deceased COVID-19 patients.

The mean chromatin accessibility at admission for patients retrospectively classified as Deceased or Alive
are shown as black and green lines, respectively. Shades indicate the standard deviation of the mean for
each group. At the bottom, a red bar denotes the regions contrasted in the "Deceased vs Alive" comparison
with its corresponding *p* value.



Suppl Figure 9. Non-random overlap between DAC for "Deceased" patient monocytes at admission
with hospitalized COVID-19 GWAS loci.

81 The evaluation of a non-random overlap between DAC regions with five significant/suggestive GWAS loci 82 for hospitalized COVDI-19 patients was performed using a permutation test. Genomic regions of equal 83 length to the five GWAS loci were permuted across the human genome while the genomic position for all 84 959 "Deceased vs Alive" DAC regions for monocytes at admission (A), and for the subset of 481 DAC 85 located in promoter regions (B). The bar plots summarize the number of permuted GWAS loci overlapping 86 a DAC region in the x-axis with the grey bars representing the density plotted in the y-axis. The black vertical line (Evperm) indicates the average number of permuted GWAS loci encompassing a DAC; the red 87 88 line represents the 95 percentile of the distribution; and the green line (Ev_{obs}) highlights the number of 89 GWAS loci with a DAC in our study.



90

91 Suppl Figure 10. Differential DNA methylation among COVID-19 patients.

92 (A) A total of 222,751 DMLs were identified for the "Deceased vs Alive" patient comparison at admission. 93 Hyper ($\Delta\beta > 0$) and hypomethylated ($\Delta\beta <=0$) CpGs were plotted against their corresponding p values. The 94 color gradient indicates the density of CpGs. (B) AreasStats of hyper (areaStat > 0) and hypomethylated 95 (areaStat < 0) regions were plotted against the number of CpGs located in the DMR for "Deceased vs Alive" 96 patients at admission (red indicates hypermethylated DMRs and olive green indicates hypomethylated 97 DMRs). (C) A total of 491,208 DMLs were detected for the "Deceased vs Alive" patient groups at follow-98 up. Hyper and hypomethylated CpGs were plotted against their corresponding p values. (D) AreasStats of 99 hyper (areaStat > 0) and hypomethylated (areaStat < 0) regions were plotted against the number of CpGs 100 located in the DMR for "Deceased vs Alive" patients at follow-up.



103 Suppl Figure 11: Comparison of monocytes DNA methylation at admission and follow-up. 104 (A) Number and percentages of overlapping DMRs between monocytes of patients classified on the disease 105 outcome ("Deceased vs Alive") at the time of admission and follow-up. Overall intersecting percentages 106 for both hyper and hypomethylated DMRs are shown on the left. (B) Gene ontology and pathway 107 enrichment analyses for DMRs at follow-up. Each bubble indicates an ontology or pathway for each of the 108 three tested databases: KEGG and Reactome pathways, and Gene Ontology. The bubble size represents the 109 percentage of genes with a corresponding significant DMR at FDR <5% and shades represent the -110 log10(FDR). The total number of peaks with assigned genes per group is shown in the bar plot on the right. 111 Pathways also enriched at admission are colored in red.



114 Suppl. Figure 12: Genes in type-1 interferon signaling GO term show increased promoter

- 115 accessibility.
- 116 Box plots with normalized quantification of pileup fragments in peaks at promoter regions for "Deceased"
- and "Alive" are shown as log2 count per million (CPM) for patient groups at admission and follow-up.
- 118

119 SUPPLEMENTAL TABLES

- Suppl. Table S1: Differential gene expression analysis for each immune cell subpopulation identified byscRNAseq.
- Suppl. Table S2: Gene ontology and pathway enrichment analysis for differentially expressed genes persub-population.
- Suppl. Table S3: Differential accessible chromatin analysis in monocytes of hospitalized COVID-19
 patients.
- Suppl. Table S4: Suppl. Table S4: Gene ontology and pathway enrichment analysis for differentially
 accessible chromatin in monocytes.
- Suppl. Table S5: List of differentially methylated regions in monocytes of hospitalized COVID-19
 patients at the admission.
- **Suppl. Table S6:** List of differentially methylated regions in monocytes of hospitalized COVID-19
- 131 patients at the follow-up.
- 132 Suppl. Table S7: List of genes included in the Modules Scores.
- **133** Suppl. Table S8: WGBS sequencing coverage and SNP removal statistics.
- **Suppl. Table S9:** Intersection of gene ontology and pathway enrichment analyses.